Department of Family Medicine, Taipei MacKay Memorial Hospital, No. 92, Section 2, Zhongshan North Road, Taipei City 10449, Taiwan.
Department of Medicine, MacKay Medical College, No. 46, Sec. 3, Zhongzheng Rd., Sanzhi Dist., New Taipei City 25245, Taiwan.
Int J Environ Res Public Health. 2020 Feb 19;17(4):1320. doi: 10.3390/ijerph17041320.
We investigated the association among metabolically healthy obesity (MHO), cardiovascular disease (CVD)risk, and all-cause mortality in the Asian population. We searched databases from inception to 16 November, 2019 and pooled data using a random-effects model. Subgroup analysis was conducted according to the following comparison groups: MHNW (without overweight or underweight participants) and MHNO (non-obese, including overweight and underweight participants). Nineteen studies were included. The mean Newcastle-Ottawa Scale score was 7.8. Participants with MHO had a significantly higher CVD risk (odds ratio (OR) = 1.36, 95% confidence interval (CI) = 1.13-1.63) and significantly lower risk of all-cause mortality (OR = 0.88, 95% CI = 0.78-1.00) than the comparison group. Subgroup analyses revealed participants with MHO had a significantly higher CVD risk than MHNW participants (OR = 1.61; 95% CI = 1.24-2.08; I = 73%), but there was no significant difference compared with MHNO participants (OR, 1.04; 95% CI, 0.80-1.36; I = 68%). Participants with MHO had a significantly lower risk of all-cause mortality (OR = 0.83; 95% CI = 0.78-0.88; I = 9%) than MHNO participants, but a borderline significantly higher risk of all-cause mortality than MHNW participants (OR = 1.30; 95% CI = 0.99-1.72; I = 0%). The CVD risk and all-cause mortality of the MHO group changed depending on the control group. Thus, future studies should select control groups carefully.
我们研究了亚洲人群中代谢健康肥胖(MHO)、心血管疾病(CVD)风险和全因死亡率之间的关系。我们从成立到 2019 年 11 月 16 日在数据库中进行了检索,并使用随机效应模型汇总了数据。根据以下比较组进行亚组分析:MHNW(无超重或体重不足参与者)和 MHNO(非肥胖,包括超重和体重不足参与者)。共纳入 19 项研究。纽卡斯尔-渥太华量表评分平均为 7.8 分。与对照组相比,MHO 患者的 CVD 风险显著更高(比值比(OR)=1.36,95%置信区间(CI)=1.13-1.63),全因死亡率风险显著更低(OR=0.88,95%CI=0.78-1.00)。亚组分析显示,与 MHNW 参与者相比,MHO 参与者的 CVD 风险显著更高(OR=1.61;95%CI=1.24-2.08;I=73%),但与 MHNO 参与者相比,无显著差异(OR=1.04;95%CI=0.80-1.36;I=68%)。与 MHNO 参与者相比,MHO 参与者的全因死亡率风险显著更低(OR=0.83;95%CI=0.78-0.88;I=9%),但与 MHNW 参与者相比,全因死亡率风险有显著升高的趋势(OR=1.30;95%CI=0.99-1.72;I=0%)。MHO 组的 CVD 风险和全因死亡率变化取决于对照组。因此,未来的研究应谨慎选择对照组。